Inventor
MILLER STEVEN T
US30 patents
⚠️ This page may combine multiple inventors who share the name “MILLER STEVEN T”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ALCON UNIVERSAL LTD
6 patentsUS6372802B2Apr 16, 2002
Aniline disulfide derivatives for treating allergic diseases
ALCON UNIVERSAL LTD6 citations73
US6506802B2Jan 14, 2003
Disulfide derivatives useful for treating allergic diseases
ALCON UNIVERSAL LTD1 citations62
US6500864B1Dec 31, 2002
Disulfide derivatives useful for treating allergic diseases
ALCON UNIVERSAL LTD1 citations62
US6492552B2Dec 10, 2002
Disulfide derivatives useful for treating allergic diseases
ALCON UNIVERSAL LTD1 citations62
US6452052B1Sep 17, 2002
Aniline disulfide derivatives for treating allergic diseases
ALCON UNIVERSAL LTD2 citations62
US6492418B2Dec 10, 2002
Compositions containing a benzamide disulfide derivative for treating allergic diseases
ALCON UNIVERSAL LTD1 citations52
YANNI JOHN M
5 patentsUS8222227B2Jul 17, 2012
RNAi-mediated inhibition of histamine receptor H1-related conditions
YANNI JOHN M6 citations83
US8673873B1Mar 18, 2014
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
YANNI JOHN M1 citations62
US8618278B2Dec 31, 2013
RNAi-mediated inhibition of histamine receptor H1-related conditions
YANNI JOHN M2 citations62
US8865671B2Oct 21, 2014
RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
YANNI JOHN M0 citations51
US8541389B2Sep 24, 2013
RNAi-mediated inhibition of tumor necrosis factor α-related conditions
YANNI JOHN M0 citations50
ARROWHEAD RES CORP
5 patentsUS9206428B2Dec 8, 2015
RNAi-mediated inhibition of histamine receptor H1-related conditions
ARROWHEAD RES CORP2 citations63
US9453220B2Sep 27, 2016
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
ARROWHEAD RES CORP2 citations58
US9745585B2Aug 29, 2017
RNAi-mediated inhibition of histamine receptor H1-related conditions
ARROWHEAD RES CORP0 citations52
US9371529B2Jun 21, 2016
RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
ARROWHEAD RES CORP0 citations52
US9447419B2Sep 20, 2016
RNAi-mediated inhibition of tumor necrosis factor α-related conditions
ARROWHEAD RES CORP0 citations51
ALCON LAB INC
4 patentsUS6225327B1May 1, 2001
Compounds which inhibit human conjunctival mast cell degranulation for treating ocular allergic-type complications
ALCON LAB INC28 citations92
US5360720ANov 1, 1994
Method of preparing human conjunctival mast cells for mast cell stabilization assays
ALCON LAB INC12 citations74
US6225332B1May 1, 2001
Compositions containing histamine H2 agonists and methods of use in treating allergy and inflammation
ALCON LAB INC4 citations63
US6274160B1Aug 14, 2001
Methods of use of histamine H2 agonists in treating dry eye
ALCON LAB INC0 citations52
ALCON RES LTD
3 patentsUS8017592B2Sep 13, 2011
RNAi-mediated inhibition of histamine receptor H1-related conditions
ALCON RES LTD5 citations74
US8048863B2Nov 1, 2011
RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
ALCON RES LTD3 citations63
US7732421B2Jun 8, 2010
RNAI-mediated inhibition of tumor necrosis factor α-related conditions
ALCON RES LTD4 citations62
ALCON INC
3 patentsUS7713975B1May 11, 2010
3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases
ALCON INC7 citations72
US7799778B1Sep 21, 2010
5-substituted 2-aminopyridine analogs for treating allergic and inflammatory diseases
ALCON INC2 citations61
US7906512B2Mar 15, 2011
3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases
ALCON INC0 citations51